HVTN 205

Status:Completed
Phase:II
Principal Investigator(s):Paul A Goepfert, MD, UAB
Objective:To evaluate the safety of and immune response to a two-vaccine regimen in healthy, HIV-uninfected adults who have never received an HIV preventive vaccine before. last updated March 27, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionParticipants will receive two injections of the JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive two injections of the JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
Mode of DeliveryIntramuscular
ARMsExperimental
Results: Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials
Official Code: NCT00820846
Related Publications:
A brief history of HIV vaccine research: stepping back to the drawing board?
HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand
Trial Sponsors: NIAID
Start Date
End Date
January 1, 2009
September 1, 2014
Enrollment:299
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women